[go: up one dir, main page]

CA2290974A1 - Solubilized sertraline compositions - Google Patents

Solubilized sertraline compositions Download PDF

Info

Publication number
CA2290974A1
CA2290974A1 CA002290974A CA2290974A CA2290974A1 CA 2290974 A1 CA2290974 A1 CA 2290974A1 CA 002290974 A CA002290974 A CA 002290974A CA 2290974 A CA2290974 A CA 2290974A CA 2290974 A1 CA2290974 A1 CA 2290974A1
Authority
CA
Canada
Prior art keywords
compositions
solubilized
solubilized sertraline
sertraline compositions
sertraline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002290974A
Other languages
French (fr)
Other versions
CA2290974C (en
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2290974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2290974A1 publication Critical patent/CA2290974A1/en
Application granted granted Critical
Publication of CA2290974C publication Critical patent/CA2290974C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.
CA002290974A 1997-07-01 1998-06-15 Solubilized sertraline compositions Expired - Fee Related CA2290974C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
US60/051,413 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Publications (2)

Publication Number Publication Date
CA2290974A1 true CA2290974A1 (en) 1999-01-14
CA2290974C CA2290974C (en) 2004-04-27

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290974A Expired - Fee Related CA2290974C (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Country Status (34)

Country Link
EP (1) EP0999829A1 (en)
JP (1) JP2000514100A (en)
KR (1) KR100366373B1 (en)
CN (1) CN1261794A (en)
AP (1) AP1192A (en)
AR (3) AR015917A1 (en)
AU (1) AU742535B2 (en)
BG (1) BG103918A (en)
BR (1) BR9810739A (en)
CA (1) CA2290974C (en)
CO (1) CO4940495A1 (en)
DZ (1) DZ2548A1 (en)
EA (1) EA002481B1 (en)
HN (1) HN1998000102A (en)
HR (1) HRP980377A2 (en)
HU (1) HUP0002236A3 (en)
ID (1) ID23429A (en)
IL (1) IL133076A (en)
IS (1) IS5260A (en)
MA (1) MA24587A1 (en)
NO (1) NO996520L (en)
OA (1) OA11243A (en)
PA (1) PA8454301A1 (en)
PE (1) PE97199A1 (en)
PL (1) PL337804A1 (en)
SK (1) SK181099A3 (en)
TN (1) TNSN98124A1 (en)
TR (1) TR199903297T2 (en)
TW (1) TW550087B (en)
UA (1) UA67741C2 (en)
UY (1) UY25071A1 (en)
WO (1) WO1999001120A1 (en)
YU (1) YU68299A (en)
ZA (1) ZA985708B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518485A (en) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク Pharmaceutical composition giving improved drug concentration
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002017918A2 (en) 2000-08-30 2002-03-07 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
KR101500020B1 (en) * 2007-03-12 2015-03-06 디에스엠 아이피 어셋츠 비.브이. Beauty composition
EP2520299A1 (en) * 2009-12-29 2012-11-07 Kowa Co., Ltd. Solid pharmaceutical composition for oral administration
EP2520300A4 (en) * 2009-12-29 2013-05-08 Kowa Co PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
CN109908354A (en) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 Sertraline hydrochloride takes orally concentrate and its preparation process
CN114894736A (en) * 2022-05-20 2022-08-12 中化地质矿山总局地质研究院 A kind of determination method of nitrate in chloride type brine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612B1 (en) * 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
MA24587A1 (en) 1998-12-31
UY25071A1 (en) 2000-12-29
OA11243A (en) 2003-07-24
UA67741C2 (en) 2004-07-15
AR015917A1 (en) 2001-05-30
EP0999829A1 (en) 2000-05-17
WO1999001120A1 (en) 1999-01-14
PE97199A1 (en) 1999-10-05
IL133076A (en) 2003-12-10
HUP0002236A3 (en) 2003-12-29
EA199900962A1 (en) 2000-08-28
AU742535B2 (en) 2002-01-03
PA8454301A1 (en) 2000-09-29
BG103918A (en) 2000-07-31
TR199903297T2 (en) 2000-07-21
PL337804A1 (en) 2000-09-11
DZ2548A1 (en) 2003-02-08
AR040280A2 (en) 2005-03-23
JP2000514100A (en) 2000-10-24
YU68299A (en) 2002-06-19
ZA985708B (en) 2000-01-10
IS5260A (en) 1999-11-19
CO4940495A1 (en) 2000-07-24
BR9810739A (en) 2000-09-12
KR20010013365A (en) 2001-02-26
HUP0002236A2 (en) 2003-08-28
AR040279A2 (en) 2005-03-23
CA2290974C (en) 2004-04-27
AP9801280A0 (en) 1998-06-30
TW550087B (en) 2003-09-01
SK181099A3 (en) 2000-07-11
NO996520L (en) 2000-02-29
HN1998000102A (en) 1999-01-08
IL133076A0 (en) 2001-03-19
TNSN98124A1 (en) 2005-03-15
NO996520D0 (en) 1999-12-28
EA002481B1 (en) 2002-06-27
AP1192A (en) 2003-07-23
KR100366373B1 (en) 2003-01-14
ID23429A (en) 2000-04-20
HRP980377A2 (en) 1999-04-30
AU7544898A (en) 1999-01-25
CN1261794A (en) 2000-08-02

Similar Documents

Publication Publication Date Title
CA2207323A1 (en) Use of pramipexole as a neuroprotective agent
HUP0103267A2 (en) Glyphosate formulation and use thereof
AU1933500A (en) Quinoline-indole antimicrobial agents, uses and compositions related thereto
HUP0105029A3 (en) Herbicide compositions containing active agent and safener and use thereof
CA2163706A1 (en) Amino Acid Derivatives of Paclitaxel
HK1019774A1 (en) Etching composition and use thereof.
AU3117397A (en) Fire-fighting agents containing polysaccharides and fluorochemical oligomeric surfactants
HUP9801819A3 (en) Synergetic phytomicrobicide compositions and use thereof
HK1014655A1 (en) Aqueous cleaning and conditioning composition
NZ239879A (en) Cleansing composition comprising two amphoteric surfactants-one being an imidazolinium derivative, the other an aminoalkanoate or iminodialkanoate, and an insoluble conditioning agent
EP2033965A3 (en) 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
CA2320706A1 (en) 20-hete antagonists and agonists
AU7597898A (en) Use of isoflavonoids in the treatment or prevention of postpartum depression
CA2290974A1 (en) Solubilized sertraline compositions
CA2227252A1 (en) Hand cleanser comprising a blend of paramenthadienes
AU2981299A (en) Nylon 6 or 66 based compositions and films formed therefrom
AU1887399A (en) Aqueous compositions comprising complexing agents and uses therof
AU1665499A (en) Formulation of a combination comprised of opioid and alpha adrenergic agonistsand the application thereof
ZA949151B (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents.
IL126185A0 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
AU2600499A (en) Methods and compositions comprising the use of blocked b-amyloid peptide
HU9502863D0 (en) 7-azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
CA2290973A1 (en) Encapsulated solution dosage forms of sertraline
AU6872896A (en) 4,4-difluoro-3-butenylester derivatives or 4,4-difluoro-3-halogen-3-butenylester derivatives and the use thereof as pesticides
IL139874A0 (en) Coating agent and the use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed